The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC).
 
Sai-Hong Ignatius Ou
Honoraria - Pfizer; Roche Pharma AG
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Alexa Betzig Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Kyle Gowen
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Philip J. Stephens
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Honoraria - EMD Serono; Pfizer
Research Funding - Foundation Medicine
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
 
Christine Marie Lovly
Honoraria - NCCN; Novartis; Pfizer; Qiagen; Sequenom
Consulting or Advisory Role - Ariad; ARIAD; Clovis Oncology; Genoptix; Novartis; Novartis
Research Funding - AstraZeneca; Novartis
Travel, Accommodations, Expenses - Pfizer
 
Siraj Mahamed Ali
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Foundation Medicine
 
Vincent A. Miller
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Novartis; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - Novartis; Pfizer; Roche/Genentech